SHINE Technologies announced recently that it has partnered with Blue Earth Therapeutics, a company focused on developing innovative radiopharmaceuticals.

According to a release, SHINE has provided to Blue Earth Therapeutics the first supply of Ilumira, which will be used in clinical trials to assess a potential treatment for men with prostate cancer.

“Our goal with Ilumira is to give the world access to a cleaner, safer and more cost-effective and robust source of lutetium-177 to help ensure the best outcomes for cancer patients,” SHINE CEO Greg Piefer said in a statement. “We’re rapidly scaling production to meet the demand created by exciting new therapies. We’re proud to partner with Blue Earth Therapeutics to pave the way for the future of precision medicine.”

The partnership follows SHINE’s submission of a Drug Master File to the U.S. Food and Drug Administration.